



46 08-18-03

1636

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 93,354-SS)

In the Application of:

Roninson et al.

Serial No.: 10/010,167

Filing Date: 12/10/2001

For: Genes and Genetic Elements Associated
With Sensitivity to Chemotherapeutic
Drugs

) Examiner: James Ketter

) Group Art Unit: 1636

RECEIVED

AUG 21 2003

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

- In regard to the above identified application,
1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449; and cited references
 - c) Return postcard
 2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
 3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450 on August 14, 2003.

Date: August 14, 2003

Respectfully submitted,

Kevin E. Noonan, Ph.D.

Registration No. 35,303



PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 93,354-SS)

In the Application of:

Roninson et al.

Serial No.: 10/010,167

Filing Date: 12/10/2001

**For: Genes and Genetic Elements Associated
With Sensitivity to Chemotherapeutic
Drugs**

Examiner: James Ketter

Group Art Unit: 1636

RECEIVED

AUG 21 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Date: August 14, 2003

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Kevin E. Noonan
Reg. No. 35,303

AUG 15 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

Sheet	1	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
	1	5,217,889		Roninson	May 9, 2000	RECEIVED
	2	6,083,745		Gudkov et al.	July 4, 2000	
	3	6,197,521	B1	Gudkov et al.	March 6, 2001	AUG 21 2003
	4	6,060,244		Roninson	May 9, 2002	TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	5	WO	91/07492		Central Blood Laboratories Authority	May 30, 1991		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	6	Albritton et al., "A Putative Murine Ecotropic Retrovirus Receptor Gene Encodes a Multiple Membrane-Spanning Protein and Confers Susceptibility to Virus Infection", 1989, Cell 57:659-666.	
	7	Altshul et al., "Basic Local Alignment Search Tool", 1990, J. Mol. Biol. 215:403-410.	
	8	Baim et al. "A Chimeric Mammalian Transactivator Based on the Lac Repressor that is regulated by Temperature and isopropyl b-D-thiogalactopyranoside", Proc Natl Acad Sci USA 88:5072-5076 (1991).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



Substitute for form 1449A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	9	Baird et al., "Identification, Cloning and Characterization of the Escherich coli sohA Gene, a Suppressor of the htrA (degP) Null Phenotype", J. Bacteriol 172: 1587-1594 (1990).			
	10	Ballester et al., "The NF1 Locus Encodes a Protein Functionally Related to Mammalian GAP and Yeast IRA Proteins", 1990, Cell 62: 851-859.			
	11	Baltimore, "Intracellular Immunization", Nature 335: 395-396 (1988).			
	12	Barbacid, "ras GENES ¹ " 1987, Ann. Rev. Biochem. 56: 779-827.			
	13	Bender et al., "Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region", 1987, J. Virol 61: 1639-1646.			
	14	Bodine et al., "Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells", Proc Natl Acad Sci USA 87:3738-3742 (1990).			
	15	Buchberg et al., "Sequence homology shared by neurofibromatosis type-1 gene and IRA-a and IRA-2 negative regulators of the RAS cyclic AMP pathway", 1990, Nature 347:291-294.			
	16	Bunnell et al., "A Dominant Negative Mutation in Two Proteins Created by Ectopic Expression of an AU-Rich 3' Untranslated Region", Somat. Cell Mol. Genet. 16: 151-162 (1990).			
	17	Call et al., "Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus", 1990, Cell 60: 509-520.			
	18	Ch'ng et al., "Antisense RNA complementary to 3' Coding and noncoding sequences of creatine kinase is a potent inhibitor of translation in vivo", Proc. Natl. Acad. Sci. 86: 10006-10010 (1989).			
Examiner Signature			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

AUG 15 2003
U.S. PATENT & TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/010,167		
Filing Dat :	Dec m b r 10, 2001		
First Named Inventor	Roninson et al.		
Group Art Unit	1636		
Examiner Name	J. Ketter		
Sheet	3	of	13
			Attorney Docket No. 93,354-SS

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	19	Chejanovsky et al., "MutationJ. Virol. <u>64</u> : 1764-1770 (1990)."
	20	Chen et al. "Internal Duplication and Homology with Bacterial Transport Proteins in the mdr1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells" <u>47</u> :381-389 (1986).
	21	Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors", Science <u>256</u> :1550-1552 (1992).
	22	Damm et al., "A Single Point Mutation in erbA restores the erythroid transforming potential of a mutant avian erythroblastosis virus (AEV) defective in both erbA and erbB oncogenes", 1987, EMBO J. <u>6</u> : 375-382.
	23	Damm et al., "Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist", Nature, vol. 339, June 22, 1989 pages. 593-597.
	24	Daugherty et al., "Antisense RNA: Effect of Ribosome Binding Sites, Target Location, Size, and Concentration on the Translation of Specific mRNA Molecules", Gene Anal. Tech. <u>6</u> :1-16 (1989).
	25	Deiss et al., "A Genetic Tool Uses to Identify Thioredoxin as a Mediator of a Growth Inhibitory Signal", Science Vol. 252:117-120 (1991).
	26	Duerre et al., "Effect of Methylation inhibitors on Gene Expression in HL-60 Cells", 1992, Biochem. Biolog. Cell. <u>70</u> :703-711.
	27	Eliyahu et al., "Participation of p53 Cellular Tumour Antigen in Transformation of Normal Embryonic Cells", 1984, Nature <u>312</u> : 646-659.
	28	Endow, "The Emerging Kinesin Family of Microtubule Motor Protein Trends Biochem Scie <u>16</u> : 221-225 (1991).
	29	Fearon et al., "Identification of a Chromosome 19q Gene That is Altered in Colorectal Cancers", 1990, Science <u>247</u> : 49-56.

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

RECEIVED
AUG 21 2003
TECH CENTER 1600/2900

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	30	Fereira et al., "Suppression of Kinesin Expression in Cultured Hippocampal Neurons Using Antisense Oligonucleotides", J. Cell Biol 117:595-606 (1992).
	31	Fields et al., "Presence of a Potent Transcription Activating Sequence in the p53 Protein", 1990 Science, 249:1046-1049.
	32	Finlay et al., "Activating Mutations for Transformation by p53 Produce a Gene Product That Forms an hsc70-p53 Complex with an Altered Half-Life", 1988, Molec. Cell Biol. 8: 531-539.
	33	Friedman et al., "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus", 335:452-454 (1988).
	34	Friend et al., "Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein", 1987, Proc. Natl. Acad. Sci. USA 84:9059-9063.
	35	Gessler et al., "Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping", 1990, Nature 343: 774-778.
	36	Graf & Beug, "Role of the v-erbA and v-erB Oncogenes of Avian Erythroblastosis Virus in Erythroid Cell Transformation", 1983, Cell 34: 7-9.
	37	Green et al., "Mutational Analysis of HIV-1 Tat Minimal Domain Peptides: Identification of Trans-Dominant Mutants That Suppress HIV-LTR-Driven Gene Expression", Cell 58:215-223.


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

AUG 15 2003



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	5	of	13	Attorney Docket No.
				93,354-SS

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published ^{T₂}
	38	Groger et al., "Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors", Gene <u>81</u> : 285-294 (1989).
	39	Gudkov et al., "Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA", 1993, Proc. Natl. Acad. Sci. USA <u>90</u> : 3231-3235.
	40	Gussow et al., "The Human B ₂ -Microglobin Gene", J. Immunol. <u>139</u> : 3132-3138 (1987).
	41	Herskowitz, "Functional Inactivation of Genes by Dominant Negative Mutations", Nature, <u>329</u> :219-22(1987)
	42	Holzmayer et al. "Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments", Nucleic Acids Res <u>20</u> : 711-717 (1992).
	43	Hunter, "Cooperation between Oncogenes", 1991, Cell <u>64</u> : 249-270.
	44	Keown et al., "Methods for Introducing DNA into Mammalian Cells", Methods Enzymol <u>185</u> : 527-536 (1990).

RECEIVED
AUG 21 2003
TECH CENTER 1600/2900

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

JUN 15 2001

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	6	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

Complete if Known

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	45	Kern et al., "Mutant p53 proteins bind DNA abnormally in vitro", 1991, Oncogene 6: 131-136.	
	46	Kern et al., "Identification of p53 as a Sequence-Specific DNA-Binding Protein", 1991, Science 252: 1708-1711.	
	47	Kerr et al., "Excess antisense RNA from infectious recombinant SV-40 fails to inhibit expression of a transfected, interferon-inducible gene", Eur. J. Biochem 175:65-73 (1998).	
	48	Kidd V.J. "Dominant Negative Mutation in Galactosyltransferase Created by Over-Expression of a Truncated cDNA", et al., Chemical Abstracts 111(23).	
	49	Kim et al., "cDNA Cloning of MEV, a mutant Protein that Facilitates Cellular Uptake of Mevalonate, and Identification of the Point Mutation Responsible for Its Gain of Function", J. Biol. Chem 267: 23113-23121.	
	50	Kinzler et al., "Identification of a Gene Located at Chromosome 5q21 that is Mutated in Colorectal Cancers", 1987, Science 236: 70-73.	
	51	Kozak and Kabat, "Ping-Pong Amplification of a Retroviral Vector Achieves High-Level Gene Expression: Human Growth Hormone Production", J. Virol 64: 3500-3508 (1990).	
	52	Kosik et al., "The Primary Structure and Analysis of the Squid Kinesin Heavy Chain", J. Biol. Chem. 265: 3278-3283 (1990).	
	53	Kung et al., "Cytotoxic Effects of Cell Cycle Phase Specific Agents: Result of Cell Cycle Perturbation", 1990, Cancer Res. 50:7307-7317.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED
AUG 21 2003
TECH CENTER 1600/2900

AUG 15 2003

PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	7	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	54	Laforgia et al., "Receptor protein-tyrosine phosphatase γ is a candidate tumor suppressor gene at human chromosome region 3p21", 1991, Proc. Natl. Acad. Sci. USA 88: 5036-5040.
	55	Lau and Nathans, "Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: Coordinate regulation with c-fos or c-myc", EMBO J. 4:3145-3151 (1985).
	56	Lee et al., "The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity", 1987, Nature 329: 642-645.
	57	Lee et al., "Expression of Cloned rpoB Gene of Escherichia coli: a Genetic System for the Isolation of Dominant Negative Mutations and Overproduction of Defective B Subunit of RNA Polymerase", J. Bacteriol 171:3002-3007 (1989).
	58	Liu et al., "Rational approaches to the Design of Antiviral agents based on S-adenosyl-L-homocysteine hydrolase as a molecular target", 1992, Antivir. Res. 19: 247-265.
	59	Lock et al., "Differential Patterns of Anti-Tumour Drug Responses and Mechanisms of Resistance in a Series of Independently-Derived VP-16-Resistant Human Tumour Cell Lines", J. Cancer 42(3): 371-381(1988). RECEIVED AUG 21 2003 TECH CENTER 1600/2900
	60	Markowitz et al., "Construction and Use of a Safe and Efficient Amphotropic Packaging Cell Line", Virology 167: 400-406 (1988).
	61	McConkey et al., "Glucocorticoids Activate a Suicide Process in Thymocytes through an Elevation of Cytosolic Ca^{2+} Concentration", 1989, Arch. Biochem. Biophys. 269:365-370.
	62	Miller & Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques 7:980-986 (1989).

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

AUG 15 2003

PARENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Name Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

Sheet	8	of	13	Attorney Docket No.	93,354-SS
-------	---	----	----	---------------------	-----------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	63	Markowitz et al., "Construction and Use of a Safe and Efficient Amphotropic Packaging Cell Line", Virology 167: 400-406 (1988).	
	64	McConkey et al., "Glucocorticoids Activate a Suicide Process in Thymocytes through an Elevation of Cytosolic Ca ²⁺ Concentration", 1989, Arch. Biochem. Biophys. 269:365-370.	
	65	Miller & Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques 7:980-986 (1989).	
	66	Milner et al., "Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes", 1991, Molec. Cell. Biol. 11: 12-19	
	67	Montenarh & Quasier, "Two different protein-protein interactions in oligomeric complexes of SV40 large T antigen with cellular oncoprotein p53", 1989, Oncogene 4: 379-382.	
	68	Murphy & Schmike "Pxzd39: a new type of cDNA expression vector for low background, high efficiency directional cloning", Nucleic Acids Res. 19: 3403-3408 (1991).	
	69	Murphy and Efstatiadis, "Cloning vectors for expression of cDNA libraries in mammalian cells", Proc. Natl. Acad. Sci. USA 84:8277-8281.	
	70	Nakatani et al., "Isolation of an Amplified DNA Sequence in Stomach Cancer", Jpn. J. Cancer Res. 81: 707-710.	
	71	Napoli C., "Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans", The Plant Cell 2(4):279-289(1990).	

Examiner Signature		Date Considered	RECEIVED JULY 1 2003 U.S. PATENT AND TRADEMARK OFFICE 16012900
--------------------	--	-----------------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Complete if Known

				Application No.	10/010,167
				Filing Date:	Dec mber 10, 2001
				First Named Inventor	Roninson et al.
				Group Art Unit	1636
				Examiner Name	J. Ketter
Sheet	9	of	13	Attorney Docket No.	93,354-SS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	72	Navone et al. "Cloning and Expression of a Human Kinesin Heavy Chain Gene: Interaction of the COOH-terminal Domain with Cytoplasmic Microtubules in Transfected CV-1 Cells", J Cell Biol <u>117</u> : 1263-1275 (1992).		
	73	Noonan et al. "Quantitative analysis of MDRI gene expression in Human tumors by polymerase chain reaction", Proc Natl Acad Sci USA <u>87</u> :7160-7164 (1990).		
	74	O'Rourke et al., "A Potential Transcriptional Activation Element in the p53 protein", 1990, Oncogene <u>5</u> :1829-1832.		
	75	Ohara et al., "One-sided polymerase chain reaction: The Amplification of cDNA", Proc. Natl. Acad. Sci. USA <u>86</u> :5673-5677 (1989).		
	76	Parada et al., "Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation", 1984, Nature <u>312</u> : 649-651.		
	77	Patanjali et al., "Construction of a uniform-abundance (normalized) cDNA library", Proc. Natl. Acad. Sci. USA <u>88</u> :1943-1947(1991).		
	78	Patterson et al., "Suicide Selection of Mammalian Cell Mutants", Methods Enzymol <u>151</u> :121(1982).		
	79	Pauwels et al., "Rapid and automated terazolium-based colorimetric assay for the detection of anti-HIV Compounds", 1988, J. Virol. Meth. <u>20</u> : 309-321		
	80	Perlaky et al., "Increased Gr owth of NIH/3T3 Cell by Transfection with Human p120 Complementary DNA and Inhibition by a p120 Antisense Construct", 1992, Cancer Res. <u>52</u> : 428-436.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

AUG 15 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

Sheet	10	of	13	Attorney Docket No.	93,354-SS
-------	----	----	----	---------------------	-----------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	81	Powell et al., "Protection against tobacco mosaic virus in transgenic plants that express tobacco mosaic virus antisense RNA", Proc. Natl. Acad. Sci, USA <u>86</u> : 6949-6952 (1989).	
	82	Ransone et al., "Trans-dominant negative mutants of Fos and Jun", Proc. Natl. Acad. Sci. USA <u>87</u> :3806-3810 (1990).	
	83	Raycroft et al., "Transcriptional Activation by Wild-Type But Not Transforming Mutants of the p53 Anti-Oncogene", 1990, Science <u>249</u> : 1049-1051.	
	84	Rimsky et al., "Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator", Nature <u>341</u> : 453-456 (1989).	
	85	Rio et al., "A Mammalian Host-Vector System That Regulates Expression and Amplification of Transfected Genes by Temperature Induction", Science <u>227</u> :23-28 (1985).	
	86	Sap et al., "The c-erb-A protein is a high-affinity receptor for thyroid hormone", 1986, Nature <u>324</u> : 635-640.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

RECEIVED
AUG 21 2003
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

AUG 15 2003

PATENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

Sheet	11	of	13	Attorney Docket No.	93,354-SS
-------	----	----	----	---------------------	-----------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	87	Sap et al., "Repression of Transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product", 1989, Nature, 340:242-244.	
	88	Sarver et al., "Ribozymes as Potential Anti-HIV -1 Therapeutic Agents", Science 247:1222-1225 (1990).	
	89	Schneider & Banner, "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide,- Sulfoxide, and -Sulfone Groups Replacing Phosphodiester Linkages", Tetrahedron Letters 31:335 (1990).	
	90	Schwab et al., "Amplified DNA in cells of genetic melanoma of Xiphophorus", 1989, 1989, Oncogene 4:139-144.	
	91	Sczakiel G. et al., "Specific inhibition of human Immunodeficiency virus type 1 replication by RNA Transcribed in sense and antisense orientation form teh 5'leader/gag region", Bioch. Biophys. Res. Comm. 169(2):643-651 (1990).	
	92	Shen et al., "Human Multidrug-Resistant Cell Lines: Increased mdr1 Expression Can Precede Gene Amplification", Science 232: 643-645 (1986).	
	93	Shih et al., "Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin", 1979, Proc. Natl. Acad Sci. USA 76:5714-5718.	
	94	Solomon et al., "Chromosome Aberrations and Cancer", 1991, Science, 254: 1153-1160.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED
AUG 21 2003
TECH CENTER 1600
200

AUG 15 2003

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	12	of	13	Attorney Docket No.	93,354-SS
-------	----	----	----	---------------------	-----------

Complete if Known

Application No.	10/010,167
Filing Date:	December 10, 2001
First Named Inventor	Roninson et al.
Group Art Unit	1636
Examiner Name	J. Ketter

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	95	Trent et al., "Identification of a Recurring Translocation Site Involving Chromosome 6 in Human Malignant Melanoma", 1989, Cancer Res. <u>49</u> : 420-423.	
	96	Trono et al., "HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-Type Virus", Cell <u>59</u> :113-120 (1989).	
	97	Tsai-Pflugfelder et al. "Cloning and sequencing of cDNA encoding human DNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22", Proc. Natl. Acad. Sci USA <u>85</u> :7177-7181 (1988).	
	98	Uhlmann and Peyman "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews <u>90</u> : 543-584 (1990).	
	99	Vale, "Intracellular Transport Using Microtubule-Based Motors", 1987, Ann. Rev. Cell Biol. <u>3</u> :347-378.	
	100	van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA and DNA Sequences", Biotechniques <u>6</u> :958-976 (1988).	
	101	Viskochil et al., "Deletions and a Translocation Interrupt a Cloned Gene at the Neurofibromatosis Type 1 Locus", 1990, Cell <u>62</u> : 187-192.	
	102	Vogelstein et al., "Genetic Alterations During Colorectal-Tumor Development", 1988, N. Engl. J. Med. <u>319</u> :525-532.	
	103	Weinberg "Tumor Suppressor Genes", 1991, Science <u>254</u> :1138-1146.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED
AUG 21 2003
TECH CENTER 1600
1600 1600 1600 1600

Substitute for Form 1449A/PTO				Complete if Known	
				Application No.	10/010,167
				Filing Date:	December 10, 2001
				First Named Inventor	Roninson et al.
				Group Art Unit	1636
				Examiner Name	J. Ketter
(use as many sheets as necessary)					
Sheet	13	of	13	Attorney Docket No.	93,354-SS

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC, 20231